Dawnrays Pharmaceutical (Holdings) Management

Management Kriterienprüfungen 3/4

Dawnrays Pharmaceutical (Holdings)'s CEO ist Weixian Wu , ernannt in Feb 2022, hat eine Amtszeit von 2.33 Jahren. Die jährliche Gesamtvergütung beträgt CN¥3.34M , bestehend aus 65% Gehalt und 35% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.13% der Aktien des Unternehmens, im Wert von HK$2.36M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 17.8 Jahre bzw. 16.1 Jahre.

Wichtige Informationen

Weixian Wu

Geschäftsführender

CN¥3.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	65.0%
Amtszeit als Geschäftsführer	2.3yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	17.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	16.1yrs

Jüngste Management Updates

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Weixian Wu im Vergleich zu den Einnahmen von Dawnrays Pharmaceutical (Holdings) verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	CN¥3m	CN¥2m	CN¥326m
Sep 30 2023	n/a	n/a	CN¥384m
Jun 30 2023	n/a	n/a	CN¥442m
Mar 31 2023	n/a	n/a	CN¥400m
Dec 31 2022	CN¥3m	CN¥2m	CN¥358m

Vergütung im Vergleich zum Markt: WeixianDie Gesamtvergütung ($USD460.18K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD351.69K).

Entschädigung vs. Einkommen: WeixianDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Weixian Wu (55 yo)

2.3yrs

Amtszeit

CN¥3,339,000

Vergütung

Mr. Weixian Wu serves as Chief Executive Officer of Dawnrays Pharmaceutical (Holdings) Limited since February 16, 2022. He joined Nanjing PharmaRays Science and Technology Co., Ltd., a non-wholly owned sub...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kei Ling Li	Co-Founder & Executive Chairman	21.7yrs	CN¥1.05m	7.16% CN¥ 129.9m
Weixian Wu	Chief Executive Officer	2.3yrs	CN¥3.34m	0.13% CN¥ 2.4m
Yung Lai Hung	Co-Founder & Executive Director	29.4yrs	CN¥672.00k	0.13% CN¥ 2.3m
Yi Jun Wu	Chief Financial Officer	6.2yrs	keine Daten	keine Daten
Kit Ling Pang	Company Secretary	no data	keine Daten	keine Daten

17.8yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: 2348Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (17.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kei Ling Li	Co-Founder & Executive Chairman	21.7yrs	CN¥1.05m	7.16% CN¥ 129.9m
Yung Lai Hung	Co-Founder & Executive Director	21.7yrs	CN¥672.00k	0.13% CN¥ 2.3m
Hao Xi Ede	Independent Non-Executive Director	9yrs	CN¥326.00k	keine Daten
Hong Man Leung	Non-Executive Director	18.6yrs	CN¥271.00k	keine Daten
Tung Sing Lo	Independent Non-Executive Director	13.7yrs	CN¥326.00k	keine Daten
Ming Yee Lam	Independent Non-Executive Director	6.1yrs	CN¥326.00k	keine Daten

16.1yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 2348Die Vorstandsmitglieder sind sehr erfahren ( 16.1 ).

Dawnrays Pharmaceutical (Holdings) Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Chief Executive Officer recently bought HK$2.6m worth of stock

Insufficient new directors

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Final dividend of HK$0.065 announced

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Upcoming dividend of HK$0.015 per share at 7.1% yield

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

First half 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 1H 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 25, 2023

Dawnrays Pharmaceutical (Holdings) Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.073 per share at 6.2% yield

Chief Executive Officer recently bought HK$2.6m worth of stock

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Full year 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in FY 2021)

Insufficient new directors

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited(SEHK:2348) dropped from S&P Global BMI Index

Upcoming dividend of HK$0.015 per share

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.11 in 1H 2021)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2022 Results on Aug 26, 2022

Dawnrays Pharmaceutical (Holdings) Limited Declares Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.065 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Ltd Ordinary Shares Deleted from Other OTC

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dawnrays Pharmaceutical (Holdings) Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Initiation of Phase III Clinical Trial for Primary Hypercholesterolemia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 1H 2020)

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

CEO & Executive Director recently bought HK$349k worth of stock

Dawnrays Pharmaceutical (Holdings) Limited Approves Special Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.10 per share

Investor sentiment improved over the past week

Co-Founder & Executive Director recently bought HK$573k worth of stock

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.16 in FY 2019)

Dawnrays Pharmaceutical (Holdings) Limited Recommends Special Dividend for the Year Ended 31 December 2020

Co-Founder & Executive Chairman recently bought HK$425k worth of stock

Co-Founder & Executive Chairman recently bought HK$231k worth of stock

Full year 2020 earnings released

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Co-Founder & Executive Director recently bought HK$263k worth of stock

Investor sentiment deteriorated over the past week

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

New 90-day high: HK$1.04

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

CEO & Executive Director recently bought HK$894k worth of stock

First half earnings released

Upcoming Dividend of HK$0.015 Per Share

New 90-day high - HK$1.01